Study of maribavir for CMV after transplant
Part of Infections clinical trials.
This trial studies maribavir, a medication for CMV infection, in adults who have had a stem cell or solid organ transplant. It aims to see how well maribavir works when given for the first time according to Belgian guidelines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a stem cell or solid organ transplant.
- You have been diagnosed with CMV infection or disease after your transplant.
- You are starting maribavir for the first time, as approved in Belgium.
- You have not taken maribavir before this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
This study tests a new medicine called maribavir for Chinese adults who have a CMV infection that hasn't gotten better with standard treatments. It may be an option for transplant recipients who need a different approach.
This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
Hear when a new Cytomegalovirus (CMV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.